HIL Serum Indices
[HIL Serum Indices]
EPTIS factsheet 1177186 | Last revision 2024-09-24 | URL: https://www.eptis.bam.de/pts1177186 https://www.eptis.bam.de/pts1177186
| PT provider | ||||||||||||||||||||||
| PT provider | Weqas Weqas | |||||||||||||||||||||
| Based in | United Kingdom | |||||||||||||||||||||
| Language(s) | ||||||||||||||||||||||
| Remarks | Most manufacturers now include Haemolytic / Icteric / Lipaemic (HIL) Indices as part of their testing repertoire as a means of identifying these interfering parameters. The three major sample interferences found to affect the accuracy and reliability of most laboratory results are haemoglobin, lipaemia and Icterus. The aim of the Weqas HIL Serum Indices programme is to assess: the ability of the analysers HIL indices test to identify the presence of these potential interference, to determine how laboratories deal with results where indices suggest that interferences are present and to promote the harmonisation of reporting. The programme provides 3 monthly samples containing either no interferant, bilirubin, haemoglobin, intralipid (surrogate marker of turbidity) or a mix of interferants at a range of concentrations. A batch is prepared every 6 months consisting of 14 serum pools: 3 haemolysed, 3 icteric, 3 intralipid, 4 mixed and 1 negative. A total of 18 samples are dispatched every 6 months, with some pools dispatched on more than one occasion. The target value is assigned from the calculated gravimetric addition of the interferant, supported by the quantitative analysis of bilirubin, haemoglobin and triglyceride (as an approximate verification of the concentration of intralipid). Both semi-quantitative and qualitative results are accommodated. Key Features: - Liquid stable samples are supplied ready to use; no pre-analytical preparation is required. - Quantitative and qualitative reporting available. - Full range of HIL indices covered; samples with individual and combined indices distributed to assess potential interferences. For more information: https://www.weqas.com/services/eqa/serum-indices/ or contact@weqas.com | |||||||||||||||||||||
| Keywords | ||||||||||||||||||||||
| Product groups |
Health care / medical devices
|
|||||||||||||||||||||
| Testing fields |
Medical analysis
|
|||||||||||||||||||||
| Technical details | ||||||||||||||||||||||
|
||||||||||||||||||||||
| Aims of the PT scheme | ||||||||||||||||||||||
| Target group of participants | The clinical usefulness of laboratory test results depends on performance evaluation and detection of errors including those that affect the integrity of the sample and presence of interferants in that sample. | |||||||||||||||||||||
| Linked to specific legislation / standards | Accreditation by UKAS based on ISO/IEC 17043. | |||||||||||||||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||||||||||||||
| Number of participants | ||||||||||||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 for part of the parameters |
|||||||||||||||||||||
| Operation is commissioned / requested by | ||||||||||||||||||||||
| Fees and frequency | ||||||||||||||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||||||||||||||
| Regularly operated | Yes (Frequency: Monthly. Samples: 3 x 1.0mL. ) | |||||||||||||||||||||
| Year of first operation | 2016 | |||||||||||||||||||||
| Contact details of the PT provider | ||||||||||||||||||||||
| Provider | Contact person | |||||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.